Skip to main content
editorial
. 2018 Jul 18;11:313–322. doi: 10.2147/IJGM.S160555

Table 4.

Typical patient scenarios and management recommendations by the expert panel

Patient scenarios Recommendations by expert panel
Primary prevention All adults ≥18 years old with a 10-year risk of ASCVD ≥7.5% (or 10% according to the Thai CV risk score) or LDL-C ≥190 mg/dL are candidates for primary prevention
Elderly (>75 years) Statins may be prescribed, with caution, taking into consideration polypharmacy and comorbidities in this population
Chronic kidney disease Statin therapy is beneficial in pre-dialysis patients. The statin dose should be adjusted according to eGFR
Type 2 diabetes All type 2 diabetes patients should receive statin therapy
Documented CVD Statin therapy with a target LDL-C ≤70 mg/dL or ≥50% reduction
Patient with ACS Maximum tolerated dose of statin with a target LDL-C ≤70 mg/dL. If the target is not achieved, add ezetimibe. In case of intolerance, decrease the statin dose and add ezetimibe
Family history of premature IHD with LDL-C <190 mg/dL Family history is an important additional risk factor and thus treatment with statin therapy should be considered

Abbreviations: ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; LDL-C, low-density lipoprotein cholesterol.